Key Publications
-
Chee, C.E., Ooi. M., Lee, SC., Sundar, R., Heong, V., Yong, WP., Ng, C.H., Wong, A., Lim, J.S.J., Tan, D. S. P., Soo, R., Tan, J.T.C., Yang, S., Thura, M., Al-Aidaroos, A. Q., Chng, W. J., Zeng, Q., Boon-Cher Goh, BC. (2023) A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies. Targeted Oncology 18(2)
-
Chia, P.L., Ang, K. H., Thura, M., and Zeng, Q. (2023) PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types. Theranostics 13(6)
-
Thura, M., Sng, J. X. E., Ang, K. W., Li, J., Gupta, A., Hong, J. M., Hong, C. W., Zeng, Q. (2021) Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Biosci Rep 43 (9):BSR20211491
-
Thura, M., Ye, Z., Al-Aidaroos, A.Q., Xiong, Q., Gupta, A., Li, J., Guo, K., Ang, K. H., and Zeng, Q. (2021) PRL3 induces Polyploid Giant Cancer Cells Eliminated by PRL3-zumab to reduce tumor relapse. Communication Biology 4:932
Our innovative antibody drugs provide new hope to
hard-to-treat cancer patients.
CONTACT US
Top
